Press releases

Breakthrough Research Published in Nature Enabled by Dynamic Single-Molecule Analysis Reveals Crucial Structure-Function Insights into DNA Repair, Resulting in New Cancer Fighting Strategies

Amsterdam, the Netherlands – July 14th, 2023 – LUMICKS, a cutting-edge life science tools company and the leading supplier of dynamic single-molecule and cell avidity analysis instruments, today announced the publication of ground-breaking cancer research in Nature. The research, enabled by LUMICKS’ C-Trap® dynamic single-molecule analysis technology, reveals new crucial…

j.yeh19 July 2023

“Avidity Enhancement” As New Strategy for Improving CAR T Therapy for AML

Press releases

Cancer Cell Paper Identifies “Avidity Enhancement” As New Strategy for Improving CAR T Therapy for Acute Myeloid Leukemia

The study details a novel strategy for better cancer treatment with CAR T cells for AML. "Avidity Enhancement", increasing cell-cell binding from both the tumor and CAR T cell side, led to a more effective eradication of tumors in mouse models of AML.

j.yeh24 May 2022

Press releases

LUMICKS Appoints Andre Nel as Chief Financial Officer

We are very pleased to attract an experienced life sciences financial executive like Andre to LUMICKS at this pivotal point in our growth. His seasoned expertise across large, global life science companies, including Illumina and Pfizer, will be invaluable to us as we accelerate our growth worldwide.

j.yeh9 May 2022

Press releases

Nature Paper Identifies “Avidity Escape” as Solid Tumor Evasion Mechanism of CAR T Cell Cancer Therapies

In this study led by the team of Dr. Marcela Maus at Harvard Medical School, the LUMICKS z-Movi® Cell Avidity Analyzer showed that loss of interferon-γ receptor (IFNγR) signaling decreased cell binding avidity between CAR T cells and their target solid tumor cells.

j.yeh2 May 2022

Press releases

LUMICKS Strengthens its Innovative C-Trap^® Solution with Launch of New Lakeview Analysis Software Platform

With the release of the Lakeview Platform, we are bridging one of the biggest hurdles in our quest to democratize dynamic single-molecule instruments: straightforward data analysis that allows scientists to translate complex data sets to biologically relevant information

j.yeh4 April 2022

Gosse Adema Professor, Radboud University Medical Centre Nijmegen

Press releases

New Study Highlights Cell Avidity’s Power to Provide Insights into the Robustness of T Cell Activation

New study by the team of Professor Gosse Adema demonstrates how cell avidity can be used to assess the effect of lead compounds on immune cells.

j.yeh22 March 2022

Press releases

Frontiers in Immunology Paper Discloses Promising New Insights into CAR-T Cell Efficacy for Cancer Therapies

Dr. Maher’s powerful research underscores the insights that our revolutionary technology can help researchers around the world discover, and help science better address core challenges in human health, particularly in designing potentially more effective immunotherapies to fight cancer.

j.yeh17 March 2022

Press releases

LUMICKS Announces 100^th Customer Placement of its C-Trap^® Product

LUMICKS has announced that it has completed installation and training for its 100th customer sale at the MRC-LMB, marking an important milestone in the company’s growth from a start-up in 2015.

j.yeh14 March 2022

Press releases

LUMICKS Unveils Groundbreaking New C-Trap^® Product at Biophysical Society Annual Meeting

New product line C-Trap ‘Edge’ adds important capabilities relevant for surface assays, which are of increasing importance in biophysical and biology research.

j.yeh18 February 2022

Press releases

New Nature Paper Relies on LUMICKS’ C-Trap^® Technology to Understand Functionality of Key Protein Involved with Incorrect DNA Repair of Dangerous Lesions Linked to Cancer Predisposition

C-Trap® technology was used in new research designed to understand the function of a key protein involved in DSB) repair. DSB repair is fundamental in maintaining the genome integrity and when compromised can lead to cancer predisposition.

j.yeh15 February 2022

Join our newsletter

First Name

Last Name

E-mail address *

Country

Get exclusive news on the latest publications, product developments, events and breakthrough science.

Application of interest *

Dynamic single-molecule analysis

Cell avidity analysis

By submitting the form you agree to LUMICKS' privacy policy. You can revoke your consent at any time.

If you are human, leave this field blank.

Cookie	Duration	Description
Boxzilla	3 days	This cookie remembers if you have already closed a modal to make sure we don't show you the same information twice.
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent	1 year	Records the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Cookie	Duration	Description
_ga	2 years	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_gat_gtag_UA_57399829_1	1 minute	Set by Google to distinguish users.
_gcl_au	3 months	Provided by Google Tag Manager to experiment advertisement efficiency of websites using their services.
_gid	1 day	Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
Clarity		Clarity is a user behavior analytics tool that helps you understand how users are interacting with our website through session replays and heatmaps.
Google Analytics Universal	1 minute	A variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
pardot	past	The pardot cookie is set while the visitor is logged in as a Pardot user. The cookie indicates an active session and is not used for tracking.
Pardot visitor	1 year	No description
Pardot visitor hashed	1 year	The Pardot cookie to link visitors to prospects

Cookie	Duration	Description
Cience		Tracking performance of Cience ads
Linkedin Insight		The LinkedIn Insight tag helps us keep track of conversions and traffic coming from the LinkedIn platform.
test_cookie	15 minutes	The test_cookie is set by doubleclick.net and is used to determine if the user's browser supports cookies.

Breakthrough Research Published in Nature Enabled by Dynamic Single-Molecule Analysis Reveals Crucial Structure-Function Insights into DNA Repair, Resulting in New Cancer Fighting Strategies

Cancer Cell Paper Identifies “Avidity Enhancement” As New Strategy for Improving CAR T Therapy for Acute Myeloid Leukemia

LUMICKS Appoints Andre Nel as Chief Financial Officer

Nature Paper Identifies “Avidity Escape” as Solid Tumor Evasion Mechanism of CAR T Cell Cancer Therapies

LUMICKS Strengthens its Innovative C-Trap^® Solution with Launch of New Lakeview Analysis Software Platform

New Study Highlights Cell Avidity’s Power to Provide Insights into the Robustness of T Cell Activation

Frontiers in Immunology Paper Discloses Promising New Insights into CAR-T Cell Efficacy for Cancer Therapies

LUMICKS Announces 100^th Customer Placement of its C-Trap^® Product

LUMICKS Unveils Groundbreaking New C-Trap^® Product at Biophysical Society Annual Meeting

New Nature Paper Relies on LUMICKS’ C-Trap^® Technology to Understand Functionality of Key Protein Involved with Incorrect DNA Repair of Dangerous Lesions Linked to Cancer Predisposition

Recent Posts

Applications

Products

About LUMICKS

For pricing, reach out to your application scientist or account manager

Fill in our contact form, we will reach out to you!

Join our newsletter

Download our webinar recording:

Download our Cell Therapy (CAR-T, TCR, NK) applications deck

Press releases

Recent Posts

Tags

Applications

Products

About LUMICKS

For pricing, reach out to your application scientist or account manager

Fill in our contact form, we will reach out to you!

Join our newsletter

Download our webinar recording:

Download our Cell Therapy (CAR-T, TCR, NK) applications deck

Accept cookies for the best website experience